PMC:7534795 / 57150-57459 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    ts in terms of multiple inflammatory, respiratory and clinical outcomes. Recently, Bristrian proposed the use of parenteral supplementation of fish-oil emulsions, containing substantial amounts of EPA and DHA (4–6 g/d), to treat patients with severe SARS-CoV-2, in order to inhibit cytokine secretion and miti

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T405","span":{"begin":250,"end":258},"obj":"Disease"}],"attributes":[{"id":"A405","pred":"mondo_id","subj":"T405","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"ts in terms of multiple inflammatory, respiratory and clinical outcomes.\nRecently, Bristrian proposed the use of parenteral supplementation of fish-oil emulsions, containing substantial amounts of EPA and DHA (4–6 g/d), to treat patients with severe SARS-CoV-2, in order to inhibit cytokine secretion and miti"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T346","span":{"begin":143,"end":147},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_117565"}],"text":"ts in terms of multiple inflammatory, respiratory and clinical outcomes.\nRecently, Bristrian proposed the use of parenteral supplementation of fish-oil emulsions, containing substantial amounts of EPA and DHA (4–6 g/d), to treat patients with severe SARS-CoV-2, in order to inhibit cytokine secretion and miti"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T43172","span":{"begin":197,"end":200},"obj":"Chemical"},{"id":"T97134","span":{"begin":205,"end":208},"obj":"Chemical"}],"attributes":[{"id":"A44407","pred":"chebi_id","subj":"T43172","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A66329","pred":"chebi_id","subj":"T97134","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A10823","pred":"chebi_id","subj":"T97134","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A34044","pred":"chebi_id","subj":"T97134","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A90835","pred":"chebi_id","subj":"T97134","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"}],"text":"ts in terms of multiple inflammatory, respiratory and clinical outcomes.\nRecently, Bristrian proposed the use of parenteral supplementation of fish-oil emulsions, containing substantial amounts of EPA and DHA (4–6 g/d), to treat patients with severe SARS-CoV-2, in order to inhibit cytokine secretion and miti"}

    LitCovid-PD-GO-BP

    {"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T103","span":{"begin":282,"end":300},"obj":"http://purl.obolibrary.org/obo/GO_0001816"},{"id":"T104","span":{"begin":291,"end":300},"obj":"http://purl.obolibrary.org/obo/GO_0046903"}],"text":"ts in terms of multiple inflammatory, respiratory and clinical outcomes.\nRecently, Bristrian proposed the use of parenteral supplementation of fish-oil emulsions, containing substantial amounts of EPA and DHA (4–6 g/d), to treat patients with severe SARS-CoV-2, in order to inhibit cytokine secretion and miti"}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"1733","span":{"begin":229,"end":237},"obj":"Species"},{"id":"1734","span":{"begin":250,"end":260},"obj":"Species"},{"id":"1736","span":{"begin":143,"end":151},"obj":"Chemical"},{"id":"1737","span":{"begin":197,"end":200},"obj":"Chemical"},{"id":"1738","span":{"begin":205,"end":208},"obj":"Chemical"}],"attributes":[{"id":"A1733","pred":"tao:has_database_id","subj":"1733","obj":"Tax:9606"},{"id":"A1734","pred":"tao:has_database_id","subj":"1734","obj":"Tax:2697049"},{"id":"A1736","pred":"tao:has_database_id","subj":"1736","obj":"MESH:D005395"},{"id":"A1737","pred":"tao:has_database_id","subj":"1737","obj":"MESH:D015118"},{"id":"A1738","pred":"tao:has_database_id","subj":"1738","obj":"MESH:D004281"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ts in terms of multiple inflammatory, respiratory and clinical outcomes.\nRecently, Bristrian proposed the use of parenteral supplementation of fish-oil emulsions, containing substantial amounts of EPA and DHA (4–6 g/d), to treat patients with severe SARS-CoV-2, in order to inhibit cytokine secretion and miti"}